High-dose psychedelic therapy (historical)

HISTORICAL. NOT FOR USE. This entry describes a 1950s to 1960s treatment for history and recognition. It gives no doses, routes, schedules or administration details. LSD is a controlled substance; nothing here is a protocol. The usable clinical material for a therapist today is in 4B and section 5.

1. Introduction

Version followed: the Saskatchewan "psychedelic" (single high-dose) model of Osmond and Hoffer as written up in Blewett and Chwelos, Handbook for the Therapeutic Use of Lysergic Acid Diethylamide-25: Individual and Group Procedures (1959; MAPS-hosted copy, read to mid-chapter 17), checked against Costandi (2014), Krebs and Johansen's 2012 meta-analysis of the later randomised trials, and secondary accounts of Al Hubbard and Hollywood Hospital. Sources include: a summary of Erika Dyck's 2006 Social History of Medicine paper on Saskatchewan LSD treatment for alcoholism (rationale, AA links, consent forms in the case records, adverse reactions, the Addiction Research Foundation's challenge); a newspaper report of Dyck's interviews with former patients; Jesse Donaldson's 2019 article and Greg Marquis's 2023 BC Studies review on Hollywood Hospital and Hubbard; Jon Hanna's 2009 account of the Myron Stolaroff archive; two Ditman papers (the 1968 harms study, abstract only, and the full text of the 1969 controlled study in alcoholic men); a summary of Sidney Cohen's 1960 survey of complications; and secondary pages on current legal status. Further reading (not drawn on): Dyck's book Psychedelic Psychiatry (2008); her 2005 thesis; her 2005 Canadian Journal of Psychiatry paper (known only from a news release about it); the Handbook's post-session and assessment chapters; primary legal texts; and any record of FDA action against Hubbard. Claims that rest on these are marked [uncertain].

What it was. "High-dose psychedelic therapy" was not a manualised therapy. It was a treatment approach built up from about 1951 to the late 1960s, mainly for alcoholism. Psychiatrist Humphry Osmond (born Surrey, 1917) became deputy director of psychiatry at Weyburn Mental Hospital, Saskatchewan, in 1951. Within a year he and biochemist-psychiatrist Abram Hoffer began LSD experiments, and in 1953 they treated their first two alcoholic patients [source: Costandi 2014]. Osmond coined the word "psychedelic" (mind-manifesting), and Weyburn is usually named as the place it was coined [source: Costandi 2014; ScienceDaily 2005; Dyck 2006]. Work later extended to Regina and Saskatoon and to the private Hollywood Hospital in New Westminster, British Columbia. J. Ross MacLean bought that hospital in 1956, and LSD sessions with Al Hubbard ran there from 1957 [source: Verzuh 2022 review of Donaldson and Dyck, The Acid Room; Donaldson 2019; Marquis 2023]. Keith Ditman ran LSD studies in the Los Angeles area. They covered what people claimed after LSD [source: CICR archive record]; how alcoholic volunteers for LSD studies differed from those who declined [source: Krebs and Johansen 2012]; a comparison of LSD users who needed psychiatric care with users who did not [source: Ditman et al. 1968, abstract]; and a double-blind study of 99 male alcoholic volunteers at an alcoholism rehabilitation camp in San Diego County, California. Everyone in that study was told to expect LSD, but each received LSD, methylphenidate (a stimulant) or chlordiazepoxide (a sedative) [source: Ditman et al. 1969]. The drinking outcomes of that study were not reported in the paper [uncertain].

Its theory of change, as its authors framed it. The early rationale came from the "model psychosis" idea: LSD seemed to reproduce states resembling psychosis [source: ScienceDaily 2005 on Dyck 2005]. A newspaper report on Dyck's research says Osmond had noticed that alcoholics often stopped drinking after an episode of delirium tremens, and believed LSD could reproduce such an episode with the same benefit [source: Globe and Mail opinion piece on Dyck, undated]. Dyck adds that Osmond hoped a biochemical treatment would show alcoholism to be a disease rather than a moral weakness. The team came to see the intense experience, often described in spiritual terms, as the active ingredient "rather than the drug alone" [source: Dyck 2006, Blossom summary]. The approach then shifted to a "psychedelic" model. A single large dose, given inside supportive psychotherapy, was meant to produce an overwhelming experience that let the patient see his condition from a fresh perspective [source: Costandi 2014]. The 1959 Handbook describes change as three steps. The patient recognises that his current patterns are inadequate, becomes motivated to face himself, and then changes his behaviour based on "emotional insight plus acceptance" of himself. The authors argue that catharsis alone gives only temporary relief unless the person's values change [source: Blewett and Chwelos 1959]. The contrast was with British "psycholytic" therapy (Sandison), which used repeated smaller doses as an adjunct to psychoanalysis; that is a separate modality [source: Costandi 2014].

What was claimed and why it stopped. By the end of the 1960s Osmond and Hoffer reported about 2,000 patients treated and a 40 to 45% non-relapse rate at one year. The work had endorsements from an Alcoholics Anonymous co-founder and from the director of Saskatchewan's Bureau on Alcoholism [source: Costandi 2014]. Local AA chapters worked with the clinical teams, and AA co-founder Bill W. corresponded with the investigators [source: Dyck 2006, Blossom summary]. Hollywood Hospital claimed 50 to 80% "success" across more than 6,000 sessions, with no stated method of measurement [source: Verzuh 2022; Donaldson 2019]. Most early studies had no control group and were probably affected by publication bias [source: Costandi 2014]. The Addiction Research Foundation disputed the Saskatchewan results and called for properly controlled trials. Its own trials, which limited environmental support, found little or no benefit [source: Dyck 2006, Blossom summary]. Six randomised trials followed between 1966 and 1970 (Toronto, Palo Alto, Madison, Topeka, Baltimore and Sheridan, Wyoming; 536 participants). Pooled, they show a short-term benefit on alcohol misuse that was no longer significant at 12 months [source: Krebs and Johansen 2012]. In their own era these trials were read as negative. Regulation then closed the field. The US passed new drug-safety rules in 1962, and the FDA restricted LSD to investigational use. LSD was outlawed federally in the US in 1968 [source: Costandi 2014] and placed in Schedule I in 1970 [source: Wikipedia, LSD]. Sandoz stopped making LSD in 1965, and Canada made it illegal in 1968 [source: Donaldson 2019]. Donaldson gives 1966 for US illegality, which may refer to state rather than federal law [uncertain]. Verzuh's review says Hollywood Hospital's LSD room had closed by 1971 [source: Verzuh 2022]. Donaldson instead dates its sessions up to the hospital's closure in July 1975, which followed the province ending its bed subsidies in December 1974 [source: Donaldson 2019]. The two sources differ [uncertain].

2. Framework (historical course, general terms)

The framework below is the course as the 1959 Handbook describes it. It shows what was done; it is not a template [source: Blewett and Chwelos 1959 unless tagged].

Phase	Goal (as stated)	Format	Moving on
1. Selection	Pick patients thought likely to respond; get voluntary agreement	Interviews; mostly alcoholic, "psychopathic" and some neurotic patients poorly served by usual care	Rapport established; patient not hostile; consent voluntary (coercion was said to make benefit unlikely)
2. Preparation	Build trust and set expectations	Pre-treatment contacts; optional written autobiography; patient's own list of questions; day cleared	Trust judged adequate. Hostile patients got longer preparation or two therapists
3. Single drug session	An overwhelming experience leading to self-examination and self-acceptance	One long day session. Individual sessions ran about 7 to 8 hours and group sessions 12 to 14. Therapist present throughout, often with other staff	Stages followed one another (see 4A.5). Unpleasant phases were not a reason to stop
4. Night after	Contain lingering effects	Someone stays with outpatients until sleep; no driving for about a day	—
5. Follow-up	Consolidate insight	Patient writes an account a day or two later and reviews their questions. Repeat sessions were said to follow the same pattern and to be more comfortable	The post-session and assessment chapters were not read, so follow-up length and criteria are [uncertain]

Session count. The model was built around one session ("single large dose") [source: Costandi 2014]. The Handbook also discusses repeat and group sessions. How often patients in Saskatchewan or at Hollywood Hospital actually had repeat sessions was not confirmed [uncertain]. In Saskatchewan, local AA chapters sometimes helped recruit patients and provided follow-up [source: Dyck 2006, Blossom summary]. The structure and length of that follow-up were not found [uncertain].

Controlled-trial variants (1966 to 1970) [source: Krebs and Johansen 2012]:

Smart et al., Toronto. Brief orientation. Patients were not told the drug's name. No music or visual material, and patients were strapped to the bed. This was the study often blamed for ignoring "set and setting."
Hollister et al., Palo Alto. Little or no specific psychotherapy.
Ludwig et al., Madison. Session given with psychotherapy, hypnosis plus psychotherapy, or silent observation. No follow-up with the session therapist.
Bowen et al., Topeka. Group lectures beforehand, emphasis on non-verbal introspection, music, flowers and pictures.
Pahnke et al., Baltimore. Extensive individual preparation, guidance toward a "peak experience", and several review sessions.
Tomsovic and Edwards, Sheridan. Lectures and reading beforehand, one group review session.

3. Guiding principles (as the historical authors stated them, with their practical meaning then and the lesson now)

Unless tagged otherwise, each principle is sourced to Blewett and Chwelos 1959; the "Today" notes are [synthesis].

Aim is self-realisation, not adjustment. Therapy should help the patient realise their potential, not just fit social norms. Today: this widened the claims to people who were not ill, which led to celebrity and "growth" use at Hollywood Hospital.
Change needs a shift in values, not just catharsis. Don't treat the drug as merely cathartic. Today: emotional release with no follow-through is still a warning sign.
Voluntary participation. Coercion makes benefit unlikely. Today: modern informed-consent standards go far beyond this (see Harm account).
Trust is the main safeguard. The authors said that "trust must be absolute"; bad states were blamed on mistrust. Today: this placed the responsibility for adverse reactions on the patient's trust and made dependence on the therapist a central feature.
Set and setting matter. A comfortable room, music and meaningful objects. This emphasis is credited to Hubbard [source: HistoryLink, Lindholdt 2024], and the Handbook cites Hubbard's earlier work. Today: this survives in regulated trial settings.
Therapist's own drug experience is essential for understanding the patient. In group sessions one or two therapists could also take the drug. Today: therapist co-ingestion during a session is a boundary violation in any regulated context [synthesis].
Don't frighten, don't fix attention on symptoms. Frightening a patient was called "inexcusable". Avoid repeatedly asking how they feel. Today: the non-directive, calming stance survives.
Accept, don't sympathise; don't accept rationalisations. Refer the patient back to their own responsibility, and don't distract them from self-examination with reassurance. Today: confrontation in a highly suggestible state can become pressure.
The therapist doesn't put ideas into the patient's mind. This was a promise made to patients. Today: it sits uneasily with heavy suggestion (questions, role-play, guided "discussion") and with documented cases where the therapist pursued their own agenda, such as trying to change a patient's sexual orientation [source: Verzuh 2022].
Don't stop for unpleasant phases. Difficult periods were seen as part of working problems through. Today: a patient's distress was not treated as a reason to stop. That is a central ethical problem.
Contain paranoid patients. A paranoid subject should not be allowed to wander off or leave. Today: in practice this meant restricting a patient's liberty while they were impaired, with no consent framework for it [synthesis].
Record insight. Patients wrote or recorded insights during the session and wrote an account afterwards. Today: this is the forerunner of modern integration.

4. Intervention inventory

This section has two parts. 4A lists the historical components, marked NOT FOR USE, so a clinician can recognise them. Each is described in general terms, with no doses, routes or administration details, and any example language describes the historical stance rather than recommending it. 4B gives the procedures a therapist can use today with this knowledge. Most of 4B is [synthesis], because none of the primary sources deals with today's clinician.

4A. Historical components (NOT FOR USE)

4A.1 Patient selection and contraindications

Purpose (historical): to pick patients expected to respond [source: Blewett and Chwelos 1959].
What was done: Selection favoured alcoholic, "psychopathic" and some neurotic patients who had not benefited from conventional care. The authors said response was hard to predict. They expected rigid, compulsive, suspicious or withdrawn people to do poorly, especially in a first session, and linked greater insecurity to tension, illness or paranoia. They treated schizophrenia as an open question, while noting that the drug might intensify symptoms. Adolescents, older adults and people of lower intelligence were described as little studied.
Watch for (today): This was selection by expected response, not a safety screen. The handbook names no systematic medical, cardiac, seizure or withdrawal screen [uncertain: the full handbook was not read]. One later trial recorded a grand mal seizure in a man abstinent only a few days who had a history of withdrawal seizures [source: Krebs and Johansen 2012]. Every later randomised trial excluded psychosis [source: Krebs and Johansen 2012].

4A.2 Preparation

Purpose (historical): to build rapport and set expectations [source: Blewett and Chwelos 1959].
What was done: Rapport came first. Hostile patients got longer preparation or two therapists. Patients might write an autobiography, though the authors warned that for some this was unnecessary or upsetting. They prepared a list of questions to bring, cleared the whole day, arranged for family not to worry, and rested beforehand. They were told to accept strange sensations rather than fight them, that laughter and tears were normal, that the therapist would not put ideas into their mind, that losing trust would make the experience unpleasant, and that the late phase, once they felt the effects had worn off, was often the most productive. They were also told to expect tiredness and some difficulty judging distance the next day.
Example language (illustrative paraphrase of the historical orientation, not for use): "Whatever you notice, let it happen; tears or laughter are expected."
Watch for (today): The instruction that mistrust causes bad experiences places the responsibility for adverse effects on the patient. Contrast the modern trial practice of full disclosure of risks [synthesis]. In the Smart trial, patients were given only a brief orientation and were not told which drug they received [source: Krebs and Johansen 2012].

4A.3 Setting and sensory materials

Purpose (historical): to give the patient a focus and to reduce fear [source: Blewett and Chwelos 1959; Hubbard: HistoryLink 2024].
What was done: A quiet, comfortable room with places to lie down. Calls were held, visitors kept out, and staff told not to come and go. Furniture was chosen to be durable because restlessness or violence could occur, and a washroom was kept close, partly so that a paranoid patient had less chance to leave. Materials included a record player with classical music in varied moods, paintings, photographs (family photos and collections such as The Family of Man), flowers, gems, and simple food and drink. A mirror was offered only after the patient had worked through frightening self-appraisal, and was not wall-mounted. Hubbard is credited with replacing sterile hospital rooms with music and art [source: HistoryLink, Lindholdt 2024; Marquis 2023]. He also used carbogen gas before sessions as a preliminary "fitness test" [source: HistoryLink 2024; Erowid Hubbard vault; Hanna 2009].
Watch for (today): Arranging the setting to stop a patient leaving amounts to containment without consent [synthesis]. Hubbard's carbogen use was his own practice, described only in secondary and enthusiast accounts. It does not appear in the Handbook chapters read [uncertain].

4A.4 Therapist and attendant conduct during the session

Purpose (historical): to support the patient through a long, intense session [source: Blewett and Chwelos 1959].
What was done: The therapist stayed throughout, often with other staff present, and was expected to have personal experience with the drug. They were to avoid boredom, avoid getting absorbed in the music or imagery, avoid long discussion of irrelevancies, and avoid repeatedly asking how the patient felt. They were to be accepting but not sympathetic, to reassure without frightening, and to steer attention to music or pictures early on. The handbook mentions no policy on touch [uncertain]. In group sessions one or two therapists might also take the drug.
Watch for (today): Therapist intoxication, unclear roles for staff, and no written touch policy are the features that distinguish this historical practice from modern regulated two-person monitoring teams [synthesis].

4A.5 Staged guidance through the session

Purpose (historical): to move the patient from perceptual change toward self-examination and acceptance [source: Blewett and Chwelos 1959].
What was done, stage by stage:
1. Pre-onset: The therapist kept the patient from boredom, fear or symptom-watching by directing attention to art, photographs or music.
2. Onset: Described as the most uncomfortable period: perceptual change, laughter, bodily sensations. Music was used as a focus, and pain was framed as shaped by apprehension.
3. Self-examination, called "the crux of the therapeutic experience": imagery turned personal. The therapist refused rationalisations, referred the patient back to their own responsibility, and held back reassurance that would distract from it. Acceptance of self was the central task.
4. Empathic bond (mainly in groups): participants became unusually aware of one another's feelings, which depended on self-acceptance.
5. Discussion (later in the day): structured questions on identity, values and relationships, with role-play, written or recorded insights, and a return to the patient's prepared questions. The therapist was not to impose answers. The authors described a sense of unity and reduced self-concern, and the idea that "faith and anxiety" cannot coexist (Handbook paraphrase).
The authors also described a rough typology of six reaction levels. These ran from denial, "flight into ideas" and "flight into symptoms", through confusional, paranoid and psychotomimetic reactions, up to "psychedelic" acceptance and unity [source: Blewett and Chwelos 1959].
Watch for (today): Confrontation ("no rationalisations") during an altered, suggestible state, combined with the authors' own spiritual framing, is a route to undue influence [synthesis].

4A.6 Managing in-session difficulty (historical approach)

What was done [source: Blewett and Chwelos 1959]: Resistance and denial were met with encouragement to accept, not argument. Fear was met with reassurance and reframing. Sessions were not ended because of unpleasant phases. For paranoia, trust was rebuilt and the patient was kept from wandering off. For grandiosity or agitation lasting beyond about an hour, the authors advised considering further medical intervention (specifics omitted here). A later phase of stereotyped, detached behaviour was described and expected to pass. Some patients were said to remain ill or psychotic for the whole session, and the therapist was told to stay supportive rather than hostile or rejecting.
Watch for (today): No stopping rule and no patient right to withdraw are stated in the parts read [uncertain for the unread chapters].

4A.7 Group sessions

What was done [source: Blewett and Chwelos 1959]: The authors preferred individual sessions first and no more than one first-time participant per group. They judged a group of three most workable. A variant had a small, previously acquainted group sit in on one person's session. Group days were long, and the authors valued group work for staff training and research.
Watch for (today): Therapists using the drug alongside patients, and very long group sessions in which a person cannot easily step out [synthesis].

4A.8 Post-session and follow-up

What was done [source: Blewett and Chwelos 1959]: Lingering effects could recur overnight. Patients were told to relax rather than resist, someone stayed with outpatients until they slept, and patients were not to drive for about a day. A written account was asked for a day or two later, along with a review of the prepared questions. The chapters on post-session care and assessment were not read [uncertain]. In the trials, follow-up ranged from none with the session therapist (Ludwig) to several review sessions (Pahnke) [source: Krebs and Johansen 2012].

4A.9 Hubbard's private practice variant and Hollywood Hospital

What was done: Al Hubbard (1901 to 1982), known as "the Captain", had no medical training. He served about 18 months in prison for Prohibition-era smuggling and was later pardoned by President Truman. He held a ship-master's certificate and is reported to have had a mail-order science degree [source: HistoryLink 2024; Verzuh 2022; Erowid Hubbard vault]. Donaldson reports that Hubbard bought his doctorate from Taylor University, which Donaldson calls a degree mill [source: Donaldson 2019]. Marquis's review calls his professional credentials "suspect" [source: Marquis 2023]. He bought LSD legally from Sandoz and is described as Canada's only licensed LSD importer [source: Donaldson 2019]. He supplied it to psychiatrists, was nicknamed "the Johnny Appleseed of LSD", and ran fee-earning psychedelic centres in California and Vancouver [source: HistoryLink 2024; Hanna 2009]. He was a consultant to the International Foundation for Advanced Study in Menlo Park, California, which looked for LSD sources other than Sandoz. He resigned in February 1965 after conflicts with its physician, Charles Savage [source: Hanna 2009]. He reported an "angelic vision" and framed his sessions in Catholic and mystical terms [source: Verzuh 2022]. At Hollywood Hospital (owner and director J. Ross MacLean), LSD sessions ran from 1957. Fees were on a sliding scale, usually 600 to 1,000 dollars, and some patients were treated free. Patients came for alcoholism, anxiety, depression, marital discord and sexual problems, and the clientele included celebrities [source: Donaldson 2019; Verzuh 2022]. LSD was also used in attempts to "cure" homosexuality, and MacLean's 1965 report conceded that few such patients achieved the heterosexual adjustment it aimed at (as reported by Donaldson) [source: Donaldson 2019; Verzuh 2022].
Watch for (today): Hubbard held a licence to import the drug but no clinical licence, and his doctorate was reportedly bought. The pattern to recognise is legitimate drug supply and borrowed medical settings combined with unverifiable credentials [synthesis]. Reports of FDA action against him are attributed to Dyck's work, but none of the Hubbard accounts mentions any FDA action [uncertain].

4B. What a therapist does today with this knowledge

This whole subsection is [synthesis], drawing on the historical facts sourced above. Legal status is sourced where stated.

4B.1 Ask about historical or non-regulated psychedelic treatment in the history

Purpose: to find clients (now mostly elderly) or relatives of people who had LSD treatment for alcoholism or other problems, in Saskatchewan, at Hollywood Hospital, in US trials or in private practice. Also to find younger clients who have used LSD outside clinics.
Steps: (1) Add one neutral question to the substance and treatment history. (2) If yes, ask where, when, who ran it, whether they agreed freely, what they were told, and what happened afterwards. (3) Note any lasting perceptual, mood or trust after-effects. (4) Ask what meaning the experience holds for them now.
Example language (illustrative): "Some people were treated with LSD in hospitals in the 1950s and 60s, or have used psychedelics since. Has anything like that been part of your life?"
Watch for: Shame, secrecy, or idealisation ("it was the only thing that ever worked"). Either can be true; record both without judgement.

4B.2 Put historical claims in context

Purpose: to answer clients, families or referrers who cite figures like "Saskatchewan cured half of alcoholics with one trip".
Steps: (1) Acknowledge that the history is real and that the clinicians were mainstream in their time [source: ScienceDaily 2005]. (2) Explain that the success figures came from uncontrolled studies [source: Costandi 2014]. (3) Summarise the randomised trials: a short-term benefit that faded by 12 months [source: Krebs and Johansen 2012]. (4) Explain that LSD is currently available only through regulated research or special-access routes (see 4B.5). (5) Bring the conversation back to treatments available now.
Example language (illustrative): "Those results are part of real history, but most of them came without comparison groups. When the treatment was tested more carefully, the benefit was there at first and then faded."
Watch for: The client hearing this as dismissal of their hope. Keep the goal behind the request (sobriety, meaning, relief) at the centre.

4B.3 Support a client who took part in historical LSD treatment

Purpose: to help someone process an experience that may have been helpful, frightening, coerced, or all three.
Steps: (1) Let the client tell the story at their own pace, without probing for drug details. (2) Explore consent: what they were told, whether they felt free to refuse, and whether they were restrained or prevented from leaving (these are documented features of some settings [source: Krebs and Johansen 2012; Blewett and Chwelos 1959]). (3) Assess for trauma symptoms, persisting perceptual changes, and grief or anger at the institution. (4) Validate both benefit and harm. (5) If they want them, help them seek their records, legal advice or patient-advocacy support.
Example language (illustrative): "It sounds as if part of it was meaningful and part of it was done to you. We can hold both."
Watch for: Re-experiencing symptoms when the story is told. Use grounding and pace the work as you would for other medical trauma.

4B.4 Support a client harmed by conversion aims or spiritualised pressure inside a session

Purpose: Hollywood Hospital records include a session aimed at ending a patient's homosexuality [source: Verzuh 2022]. Clients may carry the effects of such aims, which today are recognised as conversion practices.
Steps: (1) Name it plainly as an attempt to change who the client is, not a treatment that failed. (2) Screen for internalised shame, depression and suicidality using your standard structured risk assessment. (3) Offer affirming therapy, or refer to it.
Example language (illustrative): "What they tried to change wasn't an illness. The harm was in the attempt."
Watch for: The client blaming their "bad trip" on themselves (the historical framing that mistrust causes bad experiences [source: Blewett and Chwelos 1959]). Gently correct this.

4B.5 Explain the legal routes to a client asking for LSD therapy

Purpose: to direct an interested client only to lawful options.
Steps: (1) Canada: LSD is in Schedule III of the Controlled Drugs and Substances Act [source: Erowid LSD legal vault 2015; Wikipedia, LSD]. It is also among the "restricted drugs" under the Food and Drug Regulations. Since 5 January 2022 (SOR/2021-271), practitioners can again request Health Canada access to restricted drugs for serious or life-threatening conditions when other therapies have failed, are unsuitable or are unavailable. Alberta's regulation listing LSD for regulated therapeutic use took effect on 16 January 2023. Health Canada issued risk-management expectations for psychedelic-assisted psychotherapy trials on 5 December 2022 [source: McCarthy Tétrault 2023]. (2) US: LSD has been federally outlawed since 1968 [source: Costandi 2014] and in Schedule I since 1970. In 2024 the FDA gave breakthrough-therapy designation to an LSD product (MM120) for generalised anxiety disorder. That is a development status, not an approval: LSD has no formally approved medical use anywhere [source: Wikipedia, LSD]. (3) UK: Class A and Schedule 1, illegal to possess or supply without a licence [source: Erowid LSD legal vault 2015]. (4) Internationally, LSD is in Schedule I of the 1971 UN Convention on Psychotropic Substances [source: Wikipedia, LSD]. These are secondary sources; check the DEA, legislation.gov.uk and Justice Laws Canada before advising [uncertain: no primary legal text]. (5) Point clients to registered clinical trials only.
Example language (illustrative): "The legal way in right now is a registered research trial or a doctor's special-access request. I can help you look at whether either fits."
Watch for: A client hearing "retreat" as equal to "trial". Explain the difference in screening, monitoring and accountability.

4B.6 Harm reduction and integration for clients who use LSD outside clinics

Purpose: to keep a client safer without facilitating illegal use.
Steps: (1) Assess psychiatric history (personal or family psychosis or bipolar disorder, current suicidality), seizure history, recent heavy drinking or withdrawal (cf. the trial seizure [source: Krebs and Johansen 2012]), cardiac problems, and current medicines. Advise review by the prescriber or a pharmacist for interactions, without discussing any dosing. (2) Make a safety plan: a sober trusted person present, no driving afterwards, and crisis contacts. (3) Explain the documented risks in general terms: acute anxiety, confusion, agitation, and later flashback-like perceptual episodes, which in one trial affected about a third of LSD recipients and often followed drinking [source: Krebs and Johansen 2012]. (4) Screen for coercive or unqualified "guides" (see the Harm account red flags). (5) Afterwards, offer integration: what happened, what it means, and what concrete change in drinking or behaviour follows. Link this to evidence-based treatment.
Example language (illustrative): "I won't help you get or take it, but if you're going to, I'd rather you were as safe as possible, and I'm here to make sense of it afterwards."
Watch for: The insight not leading to any change in behaviour, or new perceptual disturbances after the experience. If so, arrange a medical or psychiatric assessment.

4B.7 Return to evidence-based alcohol treatment

Purpose: the historical target was alcohol use disorder, so make sure the client gets current care.
Steps: (1) Assess severity and withdrawal risk, and arrange medical withdrawal management where needed. (2) Offer evidence-based psychological treatment and mutual-help options. (3) Refer to a prescriber about medications for alcohol use disorder. (4) Use the client's interest in a "transformative experience" as motivational material.
Example language (illustrative): "What you were hoping LSD would give you is a turning point. Let's build one that holds."
Watch for: All-or-nothing hopes for a single dramatic cure, which was the central promise of the historical model.

5. Handling problems

The historical responses to problems are sourced to Blewett and Chwelos (1959). Every response for a current clinician is [synthesis].

Client wants "the Saskatchewan treatment" and won't consider anything else. Historical claim: one session could transform a drinker. Response now: Validate the wish for a turning point. Give the honest evidence: uncontrolled claims, and short-term trial benefit that faded by 12 months [source: Costandi 2014; Krebs and Johansen 2012]. Explain the lawful routes (4B.5). Agree a plan for now, such as motivational work and medical review, while they explore those routes.
Client is going to a retreat or an underground "guide". Don't facilitate. Do a harm-reduction assessment and safety plan (4B.6). Name the red flags (see Harm account). Agree on post-experience integration and a crisis plan.
Frightening experience, lingering perceptual changes or flashback-like episodes after use. Normalise this as a known reaction: flashback-like episodes were reported in a trial, often after drinking [source: Krebs and Johansen 2012]. Assess for psychosis, mania, suicidality and persistent perceptual disturbance, and refer for medical or psychiatric assessment if symptoms persist or impair functioning. Advise avoiding alcohol and further hallucinogens while you assess [synthesis].
Client blames themselves for a "bad trip". The historical model said mistrust caused bad experiences [source: Blewett and Chwelos 1959]. Explain that adverse reactions are a known risk of the drug and the setting, not a personal failing.
Resistance or distrust toward you (e.g. an older client who was strapped down or misled in a trial [source: Krebs and Johansen 2012]). Expect wariness about any "treatment". Be transparent about everything you do, give choices at each step, and state that they can stop at any time.
Overwhelm during the trauma narrative. Pace and ground the work. Stabilise first and process later.
Non-adherence to alcohol treatment because "only LSD worked". Explore what specifically helped (meaning, hope, feeling accepted, being in a group) and build those into current care, for example through mutual help, values work or connection to a community.
Rupture: the client feels you dismiss a life-changing experience. Acknowledge it and repair by separating the experience (which is theirs and valid) from the claims made about the treatment (which are a matter of evidence).
Colleague proposes reviving the model. Point to current regulatory routes and the Health Canada expectations for psychedelic-psychotherapy trials (therapists, settings, informed consent [source: McCarthy Tétrault 2023]). Raise ethics concerns if unlicensed use is planned (see Harm account).
Suicidality after an experience. Use standard structured risk assessment and safety planning, including lethal-means counselling (safe storage and removal) and crisis contacts.

Harm account

What was actually done

Saskatchewan, 1953 to the late 1960s: Osmond and Hoffer gave LSD to alcoholic patients at Weyburn Mental Hospital and later at other Saskatchewan sites, reporting about 2,000 patients by the late 1960s [source: Costandi 2014]. Patients were inpatients or outpatients chosen by expected response. They went through a preparation phase that told them unpleasant experiences came from losing trust, then a single long session in a furnished room, with no stated right to stop and with paranoid patients kept from leaving [source: Blewett and Chwelos 1959]. Therapists were expected to have taken the drug themselves, and in group sessions some took it alongside patients [source: Blewett and Chwelos 1959]. Institutional records for 216 cases include consent forms, transcripts and patient-written reports, so written consent was used at least in those cases [source: Dyck 2006, Blossom summary]. What patients were told about risks, and whether any ethics review took place, was not found [uncertain]. Local AA chapters sometimes helped recruit patients [source: Dyck 2006, Blossom summary]. That put a mutual-help fellowship in the role of referrer to an experimental drug treatment [synthesis].
Hollywood Hospital, New Westminster, 1957 to 1968 (the book's span) or later: MacLean and Hubbard supervised more than 6,000 sessions for a fee-paying, partly celebrity clientele. Fees were usually 600 to 1,000 dollars on a sliding scale. Patients sought help with alcoholism, addiction, anxiety, depression, marital or sexual problems, or personal growth. Success rates of 50 to 80% were claimed with no stated method [source: Verzuh 2022; Donaldson 2019]. LSD was used in attempts to end patients' homosexuality, and MacLean's own 1965 report conceded that few such patients changed [source: Verzuh 2022; Donaldson 2019]. More than 500 patient files survive in the British Columbia provincial archives [source: Marquis 2023]. The provincial College of Physicians and the psychiatrist James Tyhurst opposed the hospital, and the College threatened to withdraw subsidies [source: Donaldson 2019]. Verzuh says the LSD room had closed by 1971, while Donaldson says the hospital closed in July 1975 [uncertain: the sources differ].
Al Hubbard: He had no medical or psychological qualification, a prior criminal conviction, and a doctorate reportedly bought from a degree mill [source: HistoryLink 2024; Verzuh 2022; Donaldson 2019]. He imported LSD legally, distributed it widely to psychiatrists and others, and ran fee-earning centres in California and Vancouver. He framed the experience in mystical and religious terms [source: HistoryLink 2024; Verzuh 2022]. In the mid-1960s the Menlo Park foundation he consulted for sought supplies from manufacturers other than Sandoz [source: Hanna 2009]. His later decline is described only in general terms: he spent his fortune and by 1980 was working as a security guard in Arizona [source: HistoryLink 2024; Donaldson 2019]. No FDA action against him was confirmed in any source [uncertain].
Controlled trials (1966 to 1970): In the Toronto trial, patients were not told which drug they received, were given no music or visual material, and were strapped to the bed. Other trials left patients largely alone or gave little therapy [source: Krebs and Johansen 2012].
Ditman, Los Angeles area: In his 1969 double-blind study, 99 male alcoholic volunteers at a rehabilitation camp each had one session with LSD, methylphenidate or chlordiazepoxide. All had been told to expect LSD. Volunteers were screened to exclude severe depression, psychosis, chronic drug use including previous LSD use, intellectual disability and serious physical disability [source: Ditman et al. 1969]. Telling everyone to expect LSD when two of the three groups did not receive it was a deliberate deception built into the design [synthesis]. His group also studied people who needed psychiatric care after LSD [source: Ditman et al. 1968, abstract].

How it caused harm

Acute psychological reactions: Paranoia, confusion, and psychotic states lasting the whole session were acknowledged by the practitioners themselves [source: Blewett and Chwelos 1959]. Dyck reports that negative or terrifying reactions occurred "in a minority of cases" in Saskatchewan, and that in one case of acute distress the session was ended medically [source: Dyck 2006, Blossom summary]. In the six randomised trials there were 8 acute reactions: bizarre behaviour, agitation, confusion, and a grand mal seizure in a recently abstinent man with a history of withdrawal seizures [source: Krebs and Johansen 2012]. In Ditman's 1969 study, LSD produced the most strong unpleasant emotion of the three drugs, especially anxiety and paranoia, including fear of dying. There were no medical emergencies [source: Ditman et al. 1969].
Field-wide complications at the time: Cohen's 1960 survey of 44 investigators covered almost 5,000 people and more than 25,000 administrations of LSD or mescaline. It recorded acute panic, transient paranoid states, self-injury, drug states lasting a day or two, short-lived depression after sessions, one convulsion, and a number of prolonged psychotic breakdowns. Serious outcomes, including rare suicides, occurred almost only in patients who were already seriously disturbed, and patients fared worse than healthy volunteers [source: Cohen 1960, Blossom summary]. The exact rates were not seen [uncertain].
Prolonged reactions: Ditman's group studied LSD users who developed depression, paranoia, psychosis or suicidal behaviour severe enough to need hospital or outpatient psychiatric care, comparing them with users who did not need care [source: Ditman et al. 1968, abstract]. The frequencies and risk factors are in the full text, which is not drawn on here [uncertain].
Delayed effects: Flashback-like perceptual episodes in about a third of LSD recipients in one trial, and residual symptoms overnight [source: Krebs and Johansen 2012; Blewett and Chwelos 1959].
Consent and autonomy: Patients had no stated right to stop, paranoid patients were kept from leaving, trial patients were restrained or not told what drug they received, and dependence on trust in the therapist was built into the method [source: Blewett and Chwelos 1959; Krebs and Johansen 2012]. In Ditman's study every participant was told to expect LSD whatever they received [source: Ditman et al. 1969]. Psychological sequelae of these practices are not systematically documented in the sources [uncertain].
Misleading promotion: Uncontrolled "cure" rates were used to recruit patients and referrers. Fee-based, celebrity-oriented practice involved a promoter with no clinical qualification and a reportedly purchased doctorate [source: Costandi 2014; Verzuh 2022; HistoryLink 2024; Donaldson 2019]. The likely harm is delay of other care and loss of money [synthesis].
Conversion aims: LSD sessions were used to try to change patients' sexual orientation, and the hospital director's own report conceded that few changed [source: Verzuh 2022; Donaldson 2019]. Gay men in such settings were at particular risk.
Who was most at risk: people with existing serious mental illness or psychotic vulnerability [source: Cohen 1960, Blossom summary]; people in or near alcohol withdrawal [source: Krebs and Johansen 2012]; gay men subjected to conversion aims [source: Donaldson 2019]; and patients with no realistic way to refuse or leave [synthesis].
Mixed legacy: In Dyck's interviews, many former Saskatchewan patients said they never drank again, some said the treatment saved their lives, and they were notably loyal to their doctors [source: Globe and Mail opinion piece on Dyck]. Clients may hold benefit and harm together.
Related, separate modality: UK psycholytic LSD therapy under Sandison led to a 2002 NHS out-of-court settlement totalling £195,000 with 43 former patients [source: Costandi 2014]. That is a separate modality; it is noted here because clients may conflate the two.
No deaths directly attributed to the Saskatchewan or Hollywood programmes are documented in the sources [uncertain]. Cohen's field-wide survey reported rare suicides, almost all in patients who were already seriously disturbed [source: Cohen 1960, Blossom summary].

Recognising it today

Phrases and rationales: "one session can cure addiction", "hitting bottom chemically" or a "safe delirium", quoted cure rates of 50 to 80% with no comparison group, "the experience, not the drug, is what heals" used to justify untrained guides, and "bad trips come from not trusting the guide" [synthesis, based on the historical claims above].
Features: a guide or facilitator with no clinical licence and a charismatic or mystical backstory; an honorific or "Dr" title that cannot be verified, or a doctorate from an unaccredited institution (cf. Hubbard [source: Donaldson 2019]); the facilitator taking the substance with clients; no screening for psychosis, seizures, withdrawal or medical risk; no right to stop or leave; physical restraint; deceiving participants about what they are given; very long group sessions; a fee-based celebrity or "growth" market; recruitment through mutual-help groups; the session used to change sexual orientation or gender identity; no follow-up or integration.
Rebrandings: "psychedelic retreats" and "ceremonies" for addiction that cite the Saskatchewan results as proof; "guides" selling single-session transformation [synthesis].
How legitimate versions differ: registered trials or authorised special access, with ethics review and informed consent, defined therapist roles, medical screening and monitoring by medical staff, and adverse-event reporting. Health Canada's 2022 notice set expectations on therapists, settings and consent [source: McCarthy Tétrault 2023].

What to do instead and how to help those harmed

Instead: offer evidence-based alcohol use disorder treatment (4B.7). Direct clients who are interested in psychedelics only to regulated trials or special-access routes (4B.5). For people who use LSD outside clinics, provide harm reduction and integration (4B.6) [synthesis].
Assessment of affected clients: taking part in historical treatment, trauma symptoms, persistent perceptual disturbance, conversion-practice sequelae, and suicide risk (4B.1, 4B.3, 4B.4) [synthesis].
Ethical, reporting and legal duties [synthesis; check your own jurisdiction]: Report unlicensed health practice or a colleague's drug administration or co-ingestion to the relevant regulator, as your professional code requires. Follow safeguarding and mandatory-reporting duties if a vulnerable adult or child is at risk. Document the client's account and any consent concerns factually. Support clients who wish to seek records, legal advice or redress. Never facilitate access to illegal substances.

Sources

Sources:

Further reading (not drawn on): books and papers cited [uncertain where relied on]:

Dyck, E. (2008). Psychedelic Psychiatry: LSD from Clinic to Campus. Johns Hopkins University Press. (Not drawn on here. The 2005 McMaster PhD thesis was refused again in October 2026.)
Dyck, E. (2005). Flashback: psychiatric experimentation with LSD in historical perspective. Canadian Journal of Psychiatry. (Only the ScienceDaily release about it was seen.)
Dyck, E. (2006). "Hitting highs at rock bottom": LSD treatment for alcoholism, 1950-1970. Social History of Medicine 19(2), 313 ff. (Known through a summary only.)
Donaldson, J., and Dyck, E. (2022). The Acid Room: The Psychedelic Trials and Tribulations of Hollywood Hospital. Anvil Press. (Known through two reviews and Donaldson's 2019 article.)
Holden, B. (2021). Seattle Mystic Alfred M. Hubbard. History Press.
Cohen, S. (1960). Lysergic acid diethylamide: side effects and complications. Journal of Nervous and Mental Disease. (Known through a summary only.)
Smart et al. (1966); Hollister et al. (1969); Ludwig et al. (1969); Bowen et al. (1970); Pahnke et al. (1970); Tomsovic and Edwards (1970); Osmond et al. (1967); Ditman et al. (1970), all as summarised in Krebs and Johansen (2012).
Ditman, Whittlesey and Hayman, "Subjective claims following the LSD experience" (CICR archive record only).

← Previous · VII-033Psycholytic therapy (historical)Next · VII-035 →LSD treatment of alcoholism (historical)